Eli Lilly's GLP-1 Drugs Fuel Explosive Growth

Eli Lillys stock is a solid buy due to its thriving GLP-1 drug business, with Q1 revenue surging 56% to $19.8 billion and adjusted earnings per share soaring 156% to $8.55. Mounjaro and Zepbound sales skyrocketed, and Foundayos approval adds to the growth. The FDAs proposed removal of tirzepatide from the shortage list could halt cheap knockoffs. Other drugs like Jaypirca, Ebglyss, Kisunla, and Omvoh are also gaining traction. Despite a higher valuation, Lillys growth justifies the premium, promising strong returns over the next five years. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/da1688141573ac9f